How social, structural, and lifestyle factors relate to prostate cancer outcomes in diverse men
Official title: Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities
Run by University of California, San Francisco · NCT07690579 · Data updated 2026-11-12
This study looks at whether social and lifestyle factors help explain differences in prostate cancer outcomes among Black, Hispanic, and Asian men who have had a radical prostatectomy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 350 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Status | Recruiting |
| Started | March 31, 2026 |
| Main results expected | March 31, 2028 |
| Study ends | March 31, 2028 |
| Registry record updated | July 8, 2026 |
| Trial ID | NCT07690579 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men with prostate cancer who have elected radical prostatectomy and have consented to participate in the UCSF Biobank, including non-UCSF participants with a medical release.
✕Probably not a fit
Patients who do not undergo radical prostatectomy or do not consent to data collection may not benefit from insights generated.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study analyzes how social determinants of health and lifestyle factors relate to prostate cancer histology among diverse racial groups. The research uses questionnaires and medical record reviews from UCSF and participating community hospitals, focusing on men who elected radical prostatectomy and are part of the UCSF Biobank. The goal is to identify previously unknown SSDH and lifestyle contributors that associate with unfavorable versus favorable cancer histology to improve risk prediction. Data are collected from existing medical records and participant questionnaires to explore disparities across race/ethnicity. No experimental interventions are performed; the study observes associations to inform future screening and treatment decisions.
Why it matters
Potential benefit: Understanding SSDH factors could improve risk prediction and guide decisions in screening, diagnosis, and treatment for diverse men with prostate cancer.
How similar studies have gone: Prior research suggests social determinants influence cancer disparities; this study extends those findings to refine histology associations across racial groups.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who have elected radical prostatectomy as prostate cancer treatment. * Participants who have agreed to participate in the Urology Biobank. Exclusion Criteria: * Participant does not plan nor schedule a radical prostatectomy (RP) procedure.
Where it's running
-
University of California, San Francisco
San Francisco, California, United States Recruiting
Study contacts
- Principal investigator: Matthew Cooperberg, MD — University of California, San Francisco
- Study coordinator: Kiana Washington
- Email: Kiana.Washington@ucsf.edu
- Phone: 415.514.8026
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mini-tumors to guide treatment for aggressive prostate cancer
We will grow tiny, patient-derived mini-tumors in the lab to test which treatments work best for men with aggressive or metastatic prostate cancer.
-
Fezolinetant to reduce hot flashes in men on androgen-deprivation therapy
This trial will test whether taking fezolinetant once daily for 4 weeks reduces how often and how severe hot flashes are in men with prostate cancer who are on androgen-deprivation therapy.
-
High-Dose-Rate Brachytherapy for Prostate Cancer Recurrence
This study is testing a new way to treat prostate cancer that has come back after previous radiation therapy, using a special type of targeted radiation guided by MRI to see if it helps patients feel better and improve their health.
-
Treatment for recurrent prostate cancer with metastases
This study is testing whether combining hormone therapy with targeted radiation or surgery can help men with recurrent prostate cancer live longer without their cancer spreading.
-
Evaluating PSMA-PET/CT for Prostate Cancer Recurrence
This study is testing if using a special imaging technique called PSMA-PET/CT can help guide better treatment for men with prostate cancer who have had a rise in their PSA levels after surgery.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.